Biotinylated Cynomolgus CD24 Protein (Primary Amine Labeling)
Catalog No: CD24-CF002
- Species
- Cynomolgus
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
Product overview
Recombinant Biotinylated Cynomolgus CD24 Protein (Primary Amine Labeling) is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Thr27-Lys54 (accession: I7GKK1-1).
Product Details
- Molecular Aliases
- CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043;CD24
- Protein Length
- Thr27-Lys54
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 30.2 kDa. Due to glycosylation, the protein migrates to 50-58 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per ug by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Cynomolgus CD24 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Cynomolgus CD24 is greater than 95% as determined by SEC-HPLC.
Background
CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
References
- Barkal AA, et al.CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.Nature. 2019 Jul 31. doi: 10.1038/s41586-019-1456-0.D
- Sun F, Wang T, Jiang J, et al. Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design[J]. Oncotarget, 2017, 8(31):51238-51252. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.